Evidence map›Paper›PMID 26690267›Full record

ArticleScientific reports2015

Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients.

Raffaela Barbano, Barbara Pasculli, Michelina Coco, Andrea Fontana, Massimiliano Copetti, Michelina Rendina, Vanna Maria Valori, Paolo Graziano, Evaristo Maiello, Vito Michele Fazio and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. An Assay for Variable Fragment Length Allele-Specific Genotyping.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  5. Article
  6. Frontiers in genetics · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Values of molecular markers in the differential diagnosis of thyroid abnormalities.Journal of cancer research and clinical oncology · 2017
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raffaela BarbanoLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Barbara PasculliLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Michelina CocoLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Andrea FontanaBiostatic Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Massimiliano CopettiBiostatic Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Michelina RendinaLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Vanna Maria ValoriDepartment of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Paolo GrazianoDepartment of Pathology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG) 71013, Italy.
Evaristo MaielloDepartment of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Vito Michele FazioLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.
Paola ParrellaLaboratory of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotundo (FG) 71013, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF codon 600 mutation testing of melanoma patients is mandatory for the choice of the most appropriate therapy in the clinical setting. Competitive allele specific TaqMan PCR (Cast-PCR) technology allows not only the selective amplification of minor alleles, but it also blocks the amplification of non-mutant allele. We genotyped codon 600 of the BRAF gene in 54 patients' samples by Cast-PCR and bidirectional direct sequence analysis. All the mutations detected by sequencing were also identified by Cast-PCR. In addition, Cast-PCR assay detected four samples carrying mutations and was able to clearly identify two mutations of uncertain interpretation by Sanger sequencing. The limit of detection of Cast-PCR was evaluated by constructing dilution curves of BRAF(V600E) and BRAF(V600K) mutated clinical samples mixed with a not-mutated specimens. Both mutations could be detected until a 1:100 mutated/not mutated ratio. Cloning and sequencing of the clones was used to confirm mutations on representative discrepant cases. Cast PCR performances were not affected by intratumour heterogeneity, and less affected by melanin content. Our results indicate that Cast-PCR is a reliable diagnostic tool for the identification of melanoma patients as eligible to be treated with TKIs and might be implemented in the clinical setting as elective screening method.

Indexed as

AllelesAdultAgedAged, 80 and overBase SequenceCloning, MolecularCodonDNA Mutational AnalysisFemaleGenetic HeterogeneityHumansLimit of DetectionMaleMelaninsMelanomaMiddle AgedCodonMelaninsProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Identifiers

PMID26690267
PMCPMC4686972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.